This recent press release
from Opexa suggests that they may be improving their methods of making the vaccine. Hopefully, this will increase the efficacy of the current vaccine and, in the future, help get people into the Phase III study more quickly once it begins.
Opexa Presents Tovaxin™ Research at Federation of Clinical Immunology Societies Annual Meeting
June 11, 2007 07:00 AM Eastern Daylight Time
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a ...